Literature DB >> 11294758

Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension.

B T Alexander1, K L Cockrell, A N Rinewalt, J N Herrington, J P Granger.   

Abstract

The purpose of this study was to determine the role of endothelin in mediating the renal hemodynamic and arterial pressure changes observed during chronic ANG II-induced hypertension. ANG II (50 ng x kg(-1) x min(-1)) was chronically infused into the jugular vein by miniosmotic pump for 2 wk in male Sprague-Dawley rats with and without endothelin type A (ET(A))-receptor antagonist ABT-627 (5 mg x kg(-1) x day(-1)) pretreatment. Arterial pressure increased in ANG II rats compared with control rats (149 +/- 5 vs. 121 +/- 6 mmHg, P < 0.05, respectively). Renal expression of preproendothelin mRNA was increased by approximately 50% in both the medulla and cortex of ANG II rats. The hypertensive effect of ANG II was completely abolished in rats pretreated with the ET(A)-receptor antagonist (114 +/- 5 mmHg, P < 0.05). Glomerular filtration rate was decreased by 33% in ANG II rats, and this response was attenuated in rats pretreated with ET(A)-receptor antagonist. These data indicate that activation of the renal endothelin system by ANG II may play an important role in mediating chronic renal and hypertensive actions of ANG II.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294758     DOI: 10.1152/ajpregu.2001.280.5.R1388

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  23 in total

1.  Contrasting effects of intervention with ETA and ETB receptor antagonists in hypertension induced by angiotensin II and high-salt diet.

Authors:  Erika I Boesen; Jennifer S Pollock; David M Pollock
Journal:  Can J Physiol Pharmacol       Date:  2010-08       Impact factor: 2.273

2.  Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension.

Authors:  Ahmed A Elmarakby; Jan M Williams; John D Imig; Jennifer S Pollock; David M Pollock
Journal:  Vascul Pharmacol       Date:  2006-09-26       Impact factor: 5.773

3.  Angiotensin II-mediated microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Lidiana D Almeida-Paula; Joseph W Harding; D Neil Granger
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

Review 4.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

5.  Postmenopausal hypertension: role of the Renin-Angiotensin system.

Authors:  Licy L Yanes; Damian G Romero; Radu Iliescu; Huimin Zhang; Deborah Davis; Jane F Reckelhoff
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

Review 6.  Hypertension in postmenopausal women.

Authors:  Roberta Lima; Marion Wofford; Jane F Reckelhoff
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 7.  Endothelin: key mediator of hypertension in preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Am J Hypertens       Date:  2011-06-16       Impact factor: 2.689

8.  Effect of electroacupuncture stimulation on expression of angiotensinogen, angiotensin II type 1 receptor, endothelin-1, and endothelin a receptor mRNA in spontaneously hypertensive rat aorta.

Authors:  Ze-Jun Huo; Dong Li; Jia Guo; Sai Li; Ning Ding; Zhi-Xin Li
Journal:  Chin J Integr Med       Date:  2016-07-13       Impact factor: 1.978

9.  Roles played by 20-HETE, angiotensin II and endothelin in mediating the hypertension in aging female spontaneously hypertensive rats.

Authors:  Roberta Lima; Licy L Yanes; Deborah D Davis; Jane F Reckelhoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-12-05       Impact factor: 3.619

Review 10.  Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension.

Authors:  Agustin Gonzalez-Vicente; Fara Saez; Casandra M Monzon; Jessica Asirwatham; Jeffrey L Garvin
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.